Abstract
Accurate knowledge of molecular structure is a prerequisite for rational drug design. X-ray diffraction has a paramount importance in providing the required structural information: the structural determination by X-ray diffraction of new drug candidates and intermediates can provide valuable information of new syntheses and parameters for quantitative structure–activity relationships. Macromolecular X-ray crystallography is an important and powerful technique used in the discovery of new medicines. The detailed analysis of crystal structures of protein–ligand complexes allows the study of the specific interactions of a particular drug with its protein target at the atomic level. Most marketed pharmaceuticals consist of molecular crystals. The arrangement of the molecules in a crystal determines its physical properties and greatly influences the processing and formulation of solid pharmaceuticals, as well as key drug properties such as dissolution rate and stability. X-ray diffraction is the main tool to characterize the drugs in solid forms. An example of the use of X-ray diffraction in the development of rifamycins is discussed.
Similar content being viewed by others
References
Agrawal S, Ashokraj Y, Bharatam PV, Pillai O, Panchagnula R (2004) Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. Eur J Pharm Sci 22:127–144. doi:10.1016/j.ejps.2004.02.011
Arora SK, Arjunan P (1992) Molecular-structure and conformation of rifamycin-S, a potent inhibitor of DNA-dependent RNA-polymerase. J Antibiot 45:428–431
Artsimovitch I, Vassylyeva MN, Svetlov D, Svetlov V, Perederina A, Igarashi N, Matsugaki N, Wakatsuki S, Tahirov TH, Vassylyev DG (2005) Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. Cell 122:351–363. doi:10.1016/j.cell.2005.07.014
Babine RE, Abdel-Meguid SS (eds) (2004) Protein crystallography in drug discovery. Wiley-VCH Verlag, Weinheim
Bacchi A, Pelizzi G (1999) Conformational variety for the ansa chain of rifamycins: comparison of observed crystal structures and molecular dynamics simulations. J Comput Aided Mol Des 13:385–396. doi:10.1023/A:1008070316079
Bacchi A, Mori G, Pelizzi G, Pelosi G, Nebuloni M, Panzone GB (1995) Polymorphism-structure relationships of rifamexil, an antibiotic rifamycin derivative. Mol Pharmacol 47:611–623
Bacchi A, Pelizzi G, Nebuloni M, Ferrari P (1998) Comprehensive study on structure-activity relationships of rifamycins: discussion of molecular and crystal structure and spectroscopic and thermochemical properties of rifamycin O. J Med Chem 41:2319–2332. doi:10.1021/jm970791o
Bacchi A, Carcelli M, Pelizzi G (2008) Sampling rifamycin conformational variety by cruising through crystal forms: implications for polymorph screening and for biological models. New J Chem 32:1725–1735. doi:10.1039/b804746d
Bernstein J (2002) Polymorphism in molecular crystals. Oxford University Press, Oxford
Bhoem H-J, Schneider G (eds) (2003) Protein-ligand interactions: from molecular recognition to drug design. Wiley-VCH Verlag, Weinheim
Brufani M, Cerrini S, Fedeli W, Vaciago A (1974) Rifamycins: an insight into biological activity based on structural investigations. J Mol Biol 87:409–435. doi:10.1016/0022-2836(74)90094-1
Brufani M, Cellai L, Cerrini S, Fedeli W, Segre A, Vaciago A (1982) Structure-activity relationships in the ansamycins: molecular structure and activity of 3-carbomethoxy rifamycin S. Mol Pharmacol 21:394–399
Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA (2001) Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901–912. doi:10.1016/S0092-8674(01)00286-0
Crowfoot D, Bunn CW, Rogers-Low BW, Turner-Jones A (1949) The Chemistry of Penicillin. 310
Ferry G (2000) Dorothy hodgkin: a life. Cold Spring Harbor Laboratory Press, New York
Floss HG, Yu T-W (2005) Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev 105:621–632. doi:10.1021/cr030112j
Fox R (2006) The history of science, medicine and technology at Oxford. Notes Rec R Soc 60:69–83
Henwood SQ, Liebenberg W, Tiedt LR, Lotter AP, De Villiers MM (2001) Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates. Drug Dev Ind Pharm 27:1017–1030. doi:10.1081/DDC-100108364
Hilfiker R (ed) (2006) Polymorphism in the pharmaceutical industry. Wiley-VCH, Weinheim
Lancini G, Zanichelli W (1977) Structure-activity relationships in rifamycins. In: Perlman D (ed) Structure-activity relationships among the semisynthetic antibiotics. Academic Press, London
Macheboeuf P, Di Guilmi AM, Job V, Vernet T, Dideberg O, Dessen A (2005) Active site restructuring regulates ligand recognition in class A penicillin-binding proteins. Proc Natl Acad Sci USA 102:577–582
Maggi N, Pallanza R, Sensi P (1965) New derivatives of rifamycin SV. Antimicrob Agents Chemother 5:765–769
Majewski M, McCallum RW (2007) Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci 333:266–270. doi:10.1097/MAJ.0b013e3180536784
Ng R (2008) Drugs: from discovery to approval. Wiley-Blackwell, London
Sensi P, Margalith P, Timbal MT (1959) Rifamycin, a new antibiotic; preliminary report. Farmaco Sci 14:146–147
Viscomi GC, Campana M, Confortini D, Barbanti MM, Braga D (2006) Eur Pat Appl. (EP 2005-4695 20050303)
Viscomi GC, Campana M, Barbanti M, Grepioni F, Polito M, Confortini D, Rosini G, Righi P, Cannata V, Braga D (2008) Crystal forms of rifaximin and their effect on pharmaceutical properties. CrystEngComm 10:1074–1081. doi:10.1039/b717887e
Wouters J, Ooms F (2001) Small molecule crystallography in drug design. Curr Pharm Des 7:529–545. doi:10.2174/1381612013397889
Author information
Authors and Affiliations
Corresponding author
Additional information
This contribution is the written, peer-reviewed version of a paper presented at the conference “The Centennial of X-Ray Diffraction (1912–2012)”, held at Accademia Nazionale dei Lincei in Rome on May 8 and 9, 2012.
Rights and permissions
About this article
Cite this article
Bacchi, A. X-ray diffraction as a tool in the path from the design of an active pharmaceutical ingredient to the tablet on the shelf. Rend. Fis. Acc. Lincei 24 (Suppl 1), 109–114 (2013). https://doi.org/10.1007/s12210-012-0199-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12210-012-0199-8